<DOC>
	<DOCNO>NCT01119313</DOCNO>
	<brief_summary>The aim study intra-individual comparison skin condition addition patient base assessment product appearance topical treatment atopic eczema .</brief_summary>
	<brief_title>Study Investigate Skin Conditions Patient Assessment LAS 41002 Treatment Atopic Eczema</brief_title>
	<detailed_description />
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>men woman age 18 year old ; two comparable treatment area ( difference local SCORAD great 3 ) opposite extremities 100 300 cm2 least one lesional region within area ≥ 20 cm² . Clinical condition atopic eczema mild moderate define local SCORAD least 5 1. erythema ≥ 2 2. lichenification ≥ 1 3. dryness ≥ 1 4. itch ≥ 1 Erlangen atopy score sum equal high 10 point ( 3 ) ; physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study ; female patient childbearing potential must either surgically sterile ( hysterectomy tubal ligation ) agree use reliable method contraception failure rate le 1 % per year use consistently correctly implant , injectables , combine oral contraceptive , intra uterine device [ IUDs ] , sexual abstinence vasectomize partner ; write informed consent obtain acne , suntan , eczema , hyperpigmentation tattoos test area ; darkskinned person whose skin color prevents ready assessment skin reaction ; evidence drug alcohol abuse ; pregnancy nursing ; UVtherapy within 6 week first treatment ; symptom clinically significant illness may influence outcome study four week study ; participation treatment phase another clinical study within last four week prior first administration investigational drug study ; know allergic reaction component study preparation , hypersensitivity cetostearyl alcohol ; treatment systemic locally act medication might counter influence study aim ( e.g . antihistamine glucocorticosteroids ) within two week study day 1and throughout study period ( exception : asthma may find patient atopic eczema , therefore inhalation corticosteroid patient asthma accompany atopic eczema allow dose exceed 1 mg/day . The dosage remain constant throughout study period ) ; contraindication accord summary product characteristic ; opinion investigator physician perform initial examination patient participate study , e.g . due probable noncompliance inability understand study give adequately informed consent ; patient institutionalized legal regulatory order</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>